Zacks Investment Research
03 Jul 2026, 18:46 UTC · 1h ago
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
03 Jul 2026, 18:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Roche's experimental drug divarasib met primary and secondary endpoints in the Phase III Krascendo 1 study, showing statistically significant improvements in progression-free and overall survival for KRAS G12C NSCLC patients. — Positive Phase III results for a potential new standard of care in a significant cancer market typically drive stock appreciation for the developer.
+0.60Divarasib demonstrated 'best-in-class' potential in a head-to-head study against competitors Amgen's Lumakras and Bristol Myers' Krazati. — Superiority or competitive parity against established incumbents increases the probability of market share capture upon approval.
+0.40The safety profile of divarasib was consistent with prior findings, with no new safety signals and manageable adverse events. — Lack of new safety concerns removes a major regulatory hurdle for FDA approval.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company reported positive phase III results for divarasib, demonstrating best-in-class potential and significant improvements in patient survival.
Its drug Krazati was outperformed in a head-to-head study by Roche's experimental candidate.
Its drug Lumakras was outperformed in a head-to-head study by Roche's experimental candidate.
[mutual] Roche's divarasib is being evaluated in a head-to-head study against Bristol Myers' Krazati for the treatment of NSCLC.
[mutual] Roche's divarasib is being evaluated in a head-to-head study against Amgen's Lumakras for the treatment of NSCLC.
[mutual] Both companies produce first-generation KRAS G12C inhibitors used as comparators in the same clinical study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors - Finance
9h ago
